By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:


Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.


February 8, 2008


Founder: Martin Shkreli

CEO: Stephen Aselage

CFO: Laura Clague


Please click here for Retrophin job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Retrophin
Symbol: RTRX


Company News
Retrophin (RTRX) To Report First Quarter 2017 Financial Results 4/21/2017 8:52:17 AM
Retrophin (RTRX) Appoints Ron Squarer To Board Of Directors 4/13/2017 9:50:32 AM
John A. Orwin Joins Retrophin (RTRX) Board Of Directors 3/24/2017 8:35:35 AM
Retrophin (RTRX) to Close Down Cambridge Operations, Cut Jobs in Consolidation Move 3/9/2017 5:58:32 AM
Retrophin (RTRX) Provides Sparsentan Regulatory Update; Reports Fourth Quarter And Full Year 2016 Financial Results 3/2/2017 10:26:21 AM
Retrophin (RTRX) To Report Fourth Quarter And Full Year 2016 Financial Results 2/16/2017 8:49:27 AM
Retrophin (RTRX) Appoints William Rote Senior Vice President, Research And Development 2/14/2017 11:40:13 AM
Retrophin (RTRX) Provides Corporate Update And 2017 Preview 1/9/2017 7:43:12 AM
Retrophin (RTRX) Appoints Elizabeth Reed General Counsel 1/5/2017 7:53:03 AM
Ligand (LGND) Partner Retrophin (RTRX) Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016 12:13:53 PM